What is Leerink Partnrs’ Forecast for STOK FY2025 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a report issued on Tuesday, November 4th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $0.05 per share for the year, down from their prior estimate of $0.20. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q4 2025 earnings at ($0.84) EPS.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The firm had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.

Other equities research analysts also recently issued research reports about the stock. Needham & Company LLC boosted their price objective on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, October 10th. BTIG Research restated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. Wedbush upped their target price on Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday. Canaccord Genuity Group raised their price target on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Stoke Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $31.00.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $22.47 on Friday. The company’s fifty day moving average is $26.40 and its two-hundred day moving average is $17.07. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $38.69. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of 33.54 and a beta of 1.32.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 5,931 shares of Stoke Therapeutics stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $25.72, for a total transaction of $152,545.32. Following the sale, the insider owned 7,195 shares of the company’s stock, valued at $185,055.40. The trade was a 45.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jonathan Allan sold 14,922 shares of the business’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $20.14, for a total value of $300,529.08. Following the transaction, the general counsel owned 18,176 shares of the company’s stock, valued at $366,064.64. This trade represents a 45.08% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 186,607 shares of company stock worth $4,224,210. Company insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Corient Private Wealth LLC acquired a new stake in Stoke Therapeutics in the second quarter worth about $7,489,000. Checkpoint Capital L.P. raised its position in shares of Stoke Therapeutics by 139.3% during the 1st quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company’s stock worth $4,859,000 after buying an additional 425,330 shares in the last quarter. Erste Asset Management GmbH bought a new stake in shares of Stoke Therapeutics during the 1st quarter worth about $2,670,000. Assenagon Asset Management S.A. lifted its stake in shares of Stoke Therapeutics by 67.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 900,272 shares of the company’s stock worth $21,156,000 after acquiring an additional 362,299 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Stoke Therapeutics in the first quarter valued at approximately $2,376,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.